S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
LON:N4P

N4 Pharma Share Forecast, Price & News

GBX 8.65
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
8.50
Now: GBX 8.65
8.79
50-Day Range
7.50
MA: GBX 9.02
12.60
52-Week Range
2
Now: GBX 8.65
16
Volume308,164 shs
Average Volume3.50 million shs
Market Capitalization£15.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system; and Nanomerics Limited to produce and test two candidate formulations using the Nuvec delivery system. N4 Pharma Plc is based in London, the United Kingdom.
N4 Pharma logo

Headlines

N4 Pharma PLC
January 23, 2021 |  cnbc.com
How Much Did N4 Pharma's (LON:N4P) CEO Pocket Last Year?
November 23, 2020 |  finance.yahoo.com
IB Plc posts N4.6bn sales increase in Q3
November 22, 2020 |  msn.com
N4 Pharma Plc Regulatory News
November 5, 2020 |  lse.co.uk
Is N4 Pharma Plc's (LON:N4P) CEO Pay Fair?
May 26, 2020 |  finance.yahoo.com
N4 Pharma Plc Share Chat
January 1, 2020 |  www.lse.co.uk
N4 Pharma Plc Share Price (N4P)
September 11, 2019 |  www.lse.co.uk
N4 Pharma Plc Share Chat (N4P)
July 4, 2019 |  www.lse.co.uk
See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1332-690061
Employees5
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£23,524.00
Cash FlowGBX 2.01 per share
Book ValueGBX 2 per share

Profitability

Miscellaneous

Market Cap£15.66 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
GBX 8.65
0.00 (0.00 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive N4P News and Ratings via Email

Sign-up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











N4 Pharma (LON:N4P) Frequently Asked Questions

What stocks does MarketBeat like better than N4 Pharma?

Wall Street analysts have given N4 Pharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but N4 Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were N4 Pharma's earnings last quarter?

N4 Pharma Plc (LON:N4P) posted its quarterly earnings data on Thursday, September, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter.
View N4 Pharma's earnings history
.

How has N4 Pharma's stock price been impacted by COVID-19?

N4 Pharma's stock was trading at GBX 2.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, N4P stock has increased by 214.5% and is now trading at GBX 8.65.
View which stocks have been most impacted by COVID-19
.

Who are N4 Pharma's key executives?

N4 Pharma's management team includes the following people:
  • Mr. Nigel James Theobald, Founder, CEO & Director (Age 57, Pay $70k)
  • Dr. David Templeton, Part-Time Exec. Director & Technical Director
  • Mr. Luke Sebastian Cairns, Exec. Director (Age 43, Pay $24k)
  • Rob Harris, Head of CMC Devel.
  • Dr. Andrew Leishman, Consultant

Who are some of N4 Pharma's key competitors?

What other stocks do shareholders of N4 Pharma own?

What is N4 Pharma's stock symbol?

N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P."

How do I buy shares of N4 Pharma?

Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is N4 Pharma's stock price today?

One share of N4P stock can currently be purchased for approximately GBX 8.65.

How much money does N4 Pharma make?

N4 Pharma has a market capitalization of £15.66 million and generates £23,524.00 in revenue each year.

How many employees does N4 Pharma have?

N4 Pharma employs 5 workers across the globe.

What is N4 Pharma's official website?

The official website for N4 Pharma is www.n4pharma.com.

Where are N4 Pharma's headquarters?

N4 Pharma is headquartered at Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom.

How can I contact N4 Pharma?

N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.